Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9J35R)

Drug Name
GNF-PF-2094 Drug Info
Synonyms
GNF-Pf-2094; CHEMBL578928; AC1LF3VX; ChemDiv3_003176; MLS000555549; REGID_for_CID_697226; ZINC73452; MolPort-002-569-783; HMS2595H06; HMS3382F08; HMS1482A08; DNDI1388215; CCG-20329; BDBM50304834; STK839621; AKOS005624964; MCULE-1058130285; IDI1_021086; SMR000147266; SR-01000110418; SR-01000110418-1; BRD-K84805375-001-01-1; N2-benzyl-N4-cyclohexyl-6-methylpyrimidine-2,4-diamine; 2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine; N*2*-Benzyl-N*4*-cyclohexyl-6-methyl-pyrimidine-2,4-diamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
697226
TTD Drug ID
DM9J35R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Debrisoquine 4-hydroxylase (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glutethimide DMGE0CW Insomnia 7A00-7A0Z Approved [2]
ISOQUINE DMR17YI Malaria 1F40-1F45 Phase 1 [3]
ICI-199441 DMEWZ80 Discovery agent N.A. Investigative [4]
ML-3163 DM3S5UC Discovery agent N.A. Investigative [5]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 Discovery agent N.A. Investigative [6]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG Discovery agent N.A. Investigative [7]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ Discovery agent N.A. Investigative [8]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol DMUGAT8 Discovery agent N.A. Investigative [8]
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol DMK4ICB Discovery agent N.A. Investigative [8]
4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine DM9UGO0 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Debrisoquine 4-hydroxylase (CYP2D6) TTVG215 CP2D6_HUMAN Inhibitor [1]

References

1 Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010 Jan 1;20(1):228-31.
2 A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78.
3 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
4 Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.
5 Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
6 Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
7 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
8 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
9 Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.